CLAIMS

What is claimed is:

1. A compound of Formula (I):



(I)

or a salt thereof, wherein:

R_1 is $–NH_2$ or $–NH(CH_3)$;

each R_2 is independently F, Cl, –CN, C_{1-4} alkyl, $–CH_2F$, $–CHF_2$, $–CF_3$, $–OCH_3$, or cyclopropyl;

each R_4 is independently F, Cl, $–CH_3$, $–CH_2F$, $–CHF_2$, $–CF_3$, or $–OCH_3$;

R_6 is hydrogen, C_{1-2} alkyl, or C_{1-2} fluoroalkyl;

m is zero, 1, 2, or 3; and

n is zero, 1, 2, or 3;

with the proviso that when R_6 is hydrogen, m is 1, 2, or 3.

2. The compound according to claim 1 or a salt thereof, wherein R_1 is $–NH_2$.

3. The compound according to claim 1 or a salt thereof, wherein R_1 is $–NH(CH_3)$.

4. The compound according to any one of claims 1-3 or a salt thereof, wherein each R_2 is independently F, –CN, $–CH_3$, or $–CF_3$.

5. The compound according to any one of claims 1-5 or a salt thereof, wherein R_6 is C_{1-2} alkyl, $–CH_2F$, $–CF_2H$, $–CF_3$, or $–CH_2CF_3$.

6. The compound according to any one of claims 1-5 or a salt thereof, wherein R_6 is $–CH_3$.

7. The compound according to any one of claims 1-5 or a salt thereof, wherein:
R_6 is $C_{1\text{-}2}$ alkyl, $-CH_2F$, $-CF_2H$, $-CF_3$, or $-CH_2CF_3$; and
m is zero.

8. The compound according to any one of claims 1-5 or a salt thereof, wherein:
R_6 is $-CH_3$; and
m is zero.

9. The compound according to any one of claims 1-5 or a salt thereof, wherein each R_4 is independently F, $-CH_3$, $-CHF_2$, or $-CF_3$.

10. The compound according to any one of claims 1-5 or a salt thereof, wherein:
each R_4 is F, $-CH_3$, $-CHF_2$, or $-CF_3$;
R_6 is hydrogen; and
m is 1 or 2.

11. The compound according to any one of claims 1-5 or a salt thereof, wherein:
each R_4 is F or $-CH_3$;
R_6 is hydrogen; and
m is 1 or 2.

12. The compound according to any one of claims 1-5 or a salt thereof, wherein:
R_4 is F or $-CH_3$;
R_6 is hydrogen; and
m is 1.

13. The compound according to claim 1, salt, stereoisomer, tautomer, or hydrate thereof, having the structure:



14. The compound according to claim 1, salt, stereoisomer, tautomer, or hydrate thereof, having the structure:



15. The compound according to claim 1, salt, stereoisomer, tautomer, or hydrate thereof, having the structure:



16. The compound according to claim 1, salt, tautomer, or hydrate thereof, having the structure:



17. The compound according to claim 1, salt, tautomer, or hydrate thereof, having the structure:



.

18. The compound according to claim 1, salt, tautomer, or hydrate thereof, having the structure:



.

19. The compound according to claim 1 or a salt thereof, wherein said compound is:

2-amino-6-(2-(2,6-dioxopiperidin-3-yl)-4-methyl-1-oxoisoindolin-5-yl)-4-methylnicotinonitrile (1);

2-amino-6-(2-(2,6-dioxopiperidin-3-yl)-6-methyl-1-oxoisoindolin-5-yl)-4-methylnicotinonitrile (2);

2-amino-6-(2-(2,6-dioxopiperidin-3-yl)-4-fluoro-1-oxoisoindolin-5-yl)-4-methylnicotinonitrile (3);

3-(5-(6-amino-4-methylpyridin-2-yl)-4-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione (4);

3-(5-(6-amino-4-(trifluoroethyl) pyridin-2-yl)-4-fluoro-1-oxoisoindolin-2-yl) piperidine-2,6-dione (5);

3-(4-fluoro-5-(4-methyl-6-(methylamino)pyridin-2-yl)-1-oxoisoindolin-2-yl) piperidine-2,6-dione (6);

3-(5-(6-amino-4,5-dimethylpyridin-2-yl)-4-fluoro-1-oxoisoindolin-2-yl) piperidine-2,6-dione (7);

3-((*S*)-5-(6-amino-4,5-dimethylpyridin-2-yl)-3-methyl-1-oxoisoindolin-2-yl) piperidine-2,6-dione (8);

3-((*R*)-5-(6-amino-4,5-dimethylpyridin-2-yl)-3-methyl-1-oxoisoindolin-2-yl) piperidine-2,6-dione (9);

2-amino-6-((3S)-2-(2,6-dioxopiperidin-3-yl)-3-methyl-1-oxoisoindolin-5-yl)-4-methylnicotinonitrile (10);

2-amino-6-((3R)-2-(2,6-dioxopiperidin-3-yl)-3-methyl-1-oxoisoindolin-5-yl)-4-methylnicotinonitrile (11);

3-((S)-5-(4,5-dimethyl-6-(methylamino)pyridin-2-yl)-3-methyl-1-oxoisoindolin-2-yl) piperidine-2,6-dione (12);

3-((R)-5-(4,5-dimethyl-6-(methylamino)pyridin-2-yl)-3-methyl-1-oxoisoindolin-2-yl) piperidine-2,6-dione (13);

6-((3S)-2-(2,6-dioxopiperidin-3-yl)-3-methyl-1-oxoisoindolin-5-yl)-4-methyl-2-(methylamino) nicotinonitrile (14);

6-((3R)-2-(2,6-dioxopiperidin-3-yl)-3-methyl-1-oxoisoindolin-5-yl)-4-methyl-2-(methylamino)nicotinonitrile (15);

3-((*S*)-5-(6-amino-4,5-dimethylpyridin-2-yl)-4-fluoro-3-methyl-1-oxoisoindolin-2-yl) piperidine-2,6-dione (16);

3-((*R*)-5-(6-amino-4,5-dimethylpyridin-2-yl)-4-fluoro-3-methyl-1-oxoisoindolin-2-yl) piperidine-2,6-dione (17);

3-(5-(6-amino-3-methylpyridin-2-yl)-4-fluoro-1-oxoisoindolin-2-yl) piperidine-2,6-dione (18);

3-(5-(6-amino-5-fluoro-4-methylpyridin-2-yl)-4-fluoro-1-oxoisoindolin-2-yl) piperidine-2,6-dione (19);

3-(5-(6-amino-3-fluoro-4-methylpyridin-2-yl)-4-fluoro-1-oxoisoindolin-2-yl) piperidine-2,6-dione (20);

3-(5-(6-amino-5-fluoro-4-methylpyridin-2-yl)-4-fluoro-3-methyl-1-oxoisoindolin-2-yl)piperidine-2,6-dione (21-22);

2-amino-6-((3*R*)-2-(2,6-dioxopiperidin-3-yl)-4-fluoro-3-methyl-1-oxoisoindolin-5-yl)-4-methylnicotinonitrile (23);

3-(*(R)*-5-(6-amino-4-methylpyridin-2-yl)-4-fluoro-3-methyl-1-oxoisoindolin-2-yl) piperidine-2,6-dione (24);

3-(*(R)*-5-(6-amino-4-(trifluoromethyl)pyridin-2-yl)-4-fluoro-3-methyl-1-oxoisoindolin-2-yl)piperidine-2,6-dione (25);

3-(*(R)*-5-(6-amino-3-methylpyridin-2-yl)-4-fluoro-3-methyl-1-oxoisoindolin-2-yl) piperidine-2,6-dione (26);

3-(*(R)*-5-(6-aminopyridin-2-yl)-4-fluoro-3-methyl-1-oxoisoindolin-2-yl) piperidine-2,6-dione (27);

(R)-3-(*(R)*-5-(6-amino-4,5-dimethylpyridin-2-yl)-4-fluoro-3-methyl-1-oxoisoindolin-2-yl)piperidine-2,6-dione 28);

3-((R)-5-(6-amino-5-fluoro-4-methylpyridin-2-yl)-4-fluoro-3-methyl-1-oxoisoindolin-2-yl)piperidine-2,6-dione (29); or

3-((*S*)-5-(6-amino-5-fluoro-4-methylpyridin-2-yl)-4-fluoro-3-methyl-1-oxoisoindolin-2-yl)piperidine-2,6-dione (30).

20. A pharmaceutical composition comprising a compound according to any one of claims 1-19 or a pharmaceutically-acceptable salt thereof; and a pharmaceutically acceptable carrier.

21. A compound according to any one of claims 1-19 for use in the treatment of cancer.

22. The compound according to claim 21, wherein said cancer is selected from cancer of the colon, gastric, pancreatic cancer, breast cancer, prostate cancer, lung cancer, ovarian cancer, cervical cancer, renal cancer, cancer of the head and neck, lymphoma, leukemia and melanoma.

23. A compound according to any one of claims 1 to 19, or a pharmaceutically acceptable salt thereof, for use in decreasing Helios protein levels, Helios activity level, or Helios expression level in the cells.

24. The compound according to claim 23, wherein Helios protein is the amino acid sequence encoded by SEQ ID NOs: 1, 2, 3, 4, or 5.

25. A compound according to any one of claims 1 to 19, or a pharmaceutically acceptable salt thereof, for use in decreasing Eos protein levels, Eos activity level, or Eos expression level in the cells.

26. The compound according to Claim 25, wherein Eos protein is the amino acid

sequence encoded by SEQ ID NOs: 7 or 8.

27. A compound according to any one of claims 1-19 for use in therapy.

28. Use of the compound according to any one of claims 1-19 in the manufacture of a medicament for the treatment of cancer.

29. The use according to claim 28, wherein said cancer is selected from cancer of the colon, gastric, pancreatic cancer, breast cancer, prostate cancer, lung cancer, ovarian cancer, cervical cancer, renal cancer, cancer of the head and neck, lymphoma, leukemia and melanoma.

30. Use of the compound according to any one of claims 1 to 19, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for decreasing Helios protein levels, Helios activity level, or Helios expression level in the cells.

31. The use according to claim 30, wherein Helios protein is the amino acid sequence encoded by SEQ ID NOs: 1, 2, 3, 4, or 5.

32. Use of the compound according to any one of claims 1 to 19, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for decreasing Eos protein levels, Eos activity level, or Eos expression level in the cells.

33. The use according to claim 32, wherein Eos protein is the amino acid sequence encoded by SEQ ID NOs: 7 or 8.